|
| 36858723 | Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial. | Lancet Oncol | 2023 |
| 36989608 | Flashback Foreword: Preoperative Therapy for Operable Breast Cancer and Clinical Features of Triple-Negative Breast Cancer. | J Clin Oncol | 2023 |
| 34932888 | The Breast Cancer Weight Loss trial (Alliance A011401): A description and evidence for the lifestyle intervention. | Obesity (Silver Spring) | 2022 |
| 35652231 | Retraction: Obesity Is Associated With Inflammation and Elevated Aromatase Expression in the Mouse Mammary Gland. | Cancer Prev Res (Phila) | 2022 |
| 35652228 | Retraction: The Prostaglandin Transporter Regulates Adipogenesis and Aromatase Transcription. | Cancer Prev Res (Phila) | 2022 |
| 35652227 | Retraction: Dietary Polyphenols Suppress Elevated Levels of Proinflammatory Mediators and Aromatase in the Mammary Gland of Obese Mice. | Cancer Prev Res (Phila) | 2022 |
| 35652226 | Retraction: Caloric Restriction Reverses Obesity-Induced Mammary Gland Inflammation in Mice. | Cancer Prev Res (Phila) | 2022 |
| 35652223 | Retraction: Pioglitazone, a PPARγ Agonist, Suppresses CYP19 Transcription: Evidence for Involvement of 15-Hydroxyprostaglandin Dehydrogenase and BRCA1. | Cancer Prev Res (Phila) | 2022 |
| 35044810 | CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer. | J Clin Oncol | 2022 |
| 32770247 | Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy. | J Natl Cancer Inst | 2021 |
| 33981951 | Physical Activity, Weight, and Outcomes in Patients Receiving Chemotherapy for Metastatic Breast Cancer (C40502/Alliance). | JNCI Cancer Spectr | 2021 |
| 33947719 | Retraction: Increased Levels of COX-2 and Prostaglandin E2 Contribute to Elevated Aromatase Expression in Inflamed Breast Tissue of Obese Women. | Cancer Discov | 2021 |
| 32125937 | Phase II Single-Arm Study of Preoperative Letrozole for Estrogen Receptor-Positive Postmenopausal Ductal Carcinoma In Situ: CALGB 40903 (Alliance). | J Clin Oncol | 2020 |
| 31815584 | Discrepancies in Financial Self-Disclosures and Open Payments Reporting Among Authors of Clinical Oncology Research Studies. | J Clin Oncol | 2020 |
| 31900377 | Withdrawal: EP<sub>2</sub> and EP<sub>4</sub> receptors regulate aromatase expression in human adipocytes and breast cancer cells: Evidence of a BRCA1 and p300 exchange. | J Biol Chem | 2020 |
| 31900378 | Withdrawal: Cyclooxygenase-2-derived prostaglandin E<sub>2</sub> stimulates <i>Id-1</i> transcription. | J Biol Chem | 2020 |
| 31802506 | Personalized Management of Chemotherapy-Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance). | J Clin Pharmacol | 2020 |
| 33095682 | Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer. | J Clin Oncol | 2020 |
| 32864625 | Alterations in <i>PTEN</i> and <i>ESR1</i> promote clinical resistance to alpelisib plus aromatase inhibitors. | Nat Cancer | 2020 |
| 32366671 | First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer. | Clin Cancer Res | 2020 |
| 32240070 | Reply to M. Hutton-Potts and A.M. Joshua. | JCO Oncol Pract | 2020 |
| 32259777 | Bridging the Gap Among Clinical Practice Guidelines for Pain Management in Cancer and Sickle Cell Disease. | J Natl Compr Canc Netw | 2020 |
| 32255722 | Bridging the Gap Among Clinical Practice Guidelines for Pain Management in Cancer and Sickle Cell Disease. | JCO Oncol Pract | 2020 |
| 27171605 | Copper-64 trastuzumab PET imaging: a reproducibility study. | Q J Nucl Med Mol Imaging | 2019 |
| 31774522 | Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Phase 2 Clinical Trial. | JAMA Netw Open | 2019 |
| 31355917 | Real transparency in medicine: Time to act. | Cancer | 2019 |
| 31546097 | Hydroxyapatite mineral enhances malignant potential in a tissue-engineered model of ductal carcinoma in situ (DCIS). | Biomaterials | 2019 |
| 31339827 | Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial. | J Clin Oncol | 2019 |
| 31276981 | Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials. | Eur J Cancer | 2019 |
| 30939096 | Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. | J Clin Oncol | 2019 |
| 30404870 | Obesity-associated Breast Inflammation among Hispanic/Latina Breast Cancer Patients. | Cancer Prev Res (Phila) | 2019 |
| 30602614 | Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up. | Oncologist | 2019 |
| 30624616 | Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer. | Ann Oncol | 2019 |
| 30452337 | Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. | J Clin Oncol | 2019 |
| 29092024 | Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. | Ann Oncol | 2018 |
| 30205045 | The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. | Cancer Cell | 2018 |
| 30037817 | Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer. | Clin Cancer Res | 2018 |
| 30345349 | Molecular determinants of post-mastectomy breast cancer recurrence. | NPJ Breast Cancer | 2018 |
| 29644507 | The Impact of Obesity on Breast Cancer. | Curr Oncol Rep | 2018 |
| 29789969 | Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study. | Breast Cancer Res Treat | 2018 |
| 29680193 | Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast Cancer. | Clin Breast Cancer | 2018 |
| 29453232 | A Randomized Multicenter Phase II Study of Docosahexaenoic Acid in Patients with a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease. | Cancer Prev Res (Phila) | 2018 |
| 29337140 | Characteristics and Prognostic Factors for Patients With HER2-overexpressing Breast Cancer and Brain Metastases in the Era of HER2-targeted Therapy: An Argument for Earlier Detection. | Clin Breast Cancer | 2018 |
| 29304773 | Breast carcinoma with 21-gene recurrence score lower than 18: rate of locoregional recurrence in a large series with clinical follow-up. | BMC Cancer | 2018 |
| 29104286 | Leptin regulation of the p53-HIF1α/PKM2-aromatase axis in breast adipose stromal cells: a novel mechanism for the obesity-breast cancer link. | Int J Obes (Lond) | 2018 |
| 28986743 | Monosomy 17 in potentially curable HER2-amplified breast cancer: prognostic and predictive impact. | Breast Cancer Res Treat | 2018 |
| 29222346 | Adiposity, Inflammation, and Breast Cancer Pathogenesis in Asian Women. | Cancer Prev Res (Phila) | 2018 |
| 29221896 | Correlative imaging reveals physiochemical heterogeneity of microcalcifications in human breast carcinomas. | J Struct Biol | 2018 |
| 27526056 | Breast carcinoma with an Oncotype Dx recurrence score <18: Rate of distant metastases in a large series with clinical follow-up. | Cancer | 2017 |
| 28364214 | Frailty and long-term mortality of older breast cancer patients: CALGB 369901 (Alliance). | Breast Cancer Res Treat | 2017 |